Ian J Constable1, Chooi-May Lai2, Aaron L Magno3, Martyn A French4, Samuel B Barone5, Steven D Schwartz6, Mark S Blumenkranz7, Mariapia A Degli-Esposti2, Elizabeth P Rakoczy8. 1. Lions Eye Institute, Nedlands, Western Australia, Australia; Centre for Ophthalmology and Visual Science, The University of Western Australia, Crawley, Western Australia, Australia; Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia. 2. Lions Eye Institute, Nedlands, Western Australia, Australia; Centre for Ophthalmology and Visual Science, The University of Western Australia, Crawley, Western Australia, Australia. 3. Lions Eye Institute, Nedlands, Western Australia, Australia. 4. School of Pathology and Laboratory Medicine, The University of Western Australia, Crawley, Western Australia, Australia; Department of Clinical Immunology, Royal Perth Hospital and PathWest Laboratory Medicine, Perth, Australia. 5. Adverum Biotechnologies, Inc, Menlo Park, California. 6. Jules Stein Eye Institute, UCLA, Los Angeles, California. 7. Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California. 8. Lions Eye Institute, Nedlands, Western Australia, Australia; Centre for Ophthalmology and Visual Science, The University of Western Australia, Crawley, Western Australia, Australia. Electronic address: Elizabeth.rakoczy@uwa.edu.au.
Abstract
PURPOSE: To assess the safety of rAAV.sFlt-1 subretinal injection in neovascular age-related macular degeneration (wet AMD) over 36 months. DESIGN: Phase 1 dose escalation trial. METHODS:Eight subjects with advanced, treatment-experienced wet AMD were randomly assigned (3:1) to treatment and non-gene therapy control groups. Eligible subjects were ≥65 years, had wet AMD, and had best-corrected visual acuity (BCVA) 10/200 to 20/80 in the study eye and 20/200 or better in the other eye. Three of the treatment group subjects received low-dose (1 × 1010 vector genomes) and 3 high-dose (1 × 1011 vector genomes) rAAV.sFLT-1 via subretinal injection. Study monitoring was monthly to the primary endpoint at month 12 and then protocol-driven follow-up study visits were conducted at months 18 and 36. All subjects received intravitreal ranibizumab at baseline and at week 4, and retreatment injections at subsequent visits based on prespecified criteria for active wet AMD. The primary endpoint was ocular and systemic safety, but exploratory data including BCVA, retinal center point thickness, and the number of ranibizumab retreatments at and between study visits were also analyzed. RESULTS: Six of the 8 subjects completed the 36-month study. Subretinal injection with parsplana vitrectomy was well tolerated in this cohort. No ocular or systemic safety signals were observed during the long-term follow-up period. Exploratory data analysis suggests stability of wet AMD over the 36-month period. CONCLUSIONS: Subretinal delivery of rAAV.sFLT-1 was well tolerated and demonstrated a favourable safety profile through month 36. Thus, rAAV.sFLT-1 could be safely considered for future evaluation in the treatment of wet AMD.
RCT Entities:
PURPOSE: To assess the safety of rAAV.sFlt-1 subretinal injection in neovascular age-related macular degeneration (wet AMD) over 36 months. DESIGN: Phase 1 dose escalation trial. METHODS: Eight subjects with advanced, treatment-experienced wet AMD were randomly assigned (3:1) to treatment and non-gene therapy control groups. Eligible subjects were ≥65 years, had wet AMD, and had best-corrected visual acuity (BCVA) 10/200 to 20/80 in the study eye and 20/200 or better in the other eye. Three of the treatment group subjects received low-dose (1 × 1010 vector genomes) and 3 high-dose (1 × 1011 vector genomes) rAAV.sFLT-1 via subretinal injection. Study monitoring was monthly to the primary endpoint at month 12 and then protocol-driven follow-up study visits were conducted at months 18 and 36. All subjects received intravitreal ranibizumab at baseline and at week 4, and retreatment injections at subsequent visits based on prespecified criteria for active wet AMD. The primary endpoint was ocular and systemic safety, but exploratory data including BCVA, retinal center point thickness, and the number of ranibizumab retreatments at and between study visits were also analyzed. RESULTS: Six of the 8 subjects completed the 36-month study. Subretinal injection with pars plana vitrectomy was well tolerated in this cohort. No ocular or systemic safety signals were observed during the long-term follow-up period. Exploratory data analysis suggests stability of wet AMD over the 36-month period. CONCLUSIONS: Subretinal delivery of rAAV.sFLT-1 was well tolerated and demonstrated a favourable safety profile through month 36. Thus, rAAV.sFLT-1 could be safely considered for future evaluation in the treatment of wet AMD.
Authors: Livia S Carvalho; Ru Xiao; Sarah J Wassmer; Aliete Langsdorf; Eric Zinn; Simon Pacouret; Samiksha Shah; Jason I Comander; Leo A Kim; Laurence Lim; Luk H Vandenberghe Journal: Hum Gene Ther Date: 2018-03-20 Impact factor: 5.695
Authors: Zhenxi Song; Liangyu Xu; Jiang Wang; Reza Rasti; Ananth Sastry; Jianwei D Li; William Raynor; Joseph A Izatt; Cynthia A Toth; Lejla Vajzovic; Bin Deng; Sina Farsiu Journal: Am J Ophthalmol Date: 2020-07-21 Impact factor: 5.258
Authors: Sanford L Boye; Shreyasi Choudhury; Sean Crosson; Giovanni Di Pasquale; Sandra Afione; Russell Mellen; Victoria Makal; Kaitlyn R Calabro; Diego Fajardo; James Peterson; Hangning Zhang; Matthew T Leahy; Colin K Jennings; John A Chiorini; Ryan F Boyd; Shannon E Boye Journal: Mol Ther Date: 2020-04-11 Impact factor: 12.910
Authors: Si Hyung Lee; Ye Seul Kim; Seung Kwan Nah; Hee Jong Kim; Ha Yan Park; Jin Young Yang; Keerang Park; Tae Kwann Park Journal: Mol Ther Methods Clin Dev Date: 2018-01-31 Impact factor: 6.698
Authors: Ye Tao; Bang Hu; Zhao Ma; Haijun Li; Enming Du; Gang Wang; Biao Xing; Jie Ma; Zongming Song Journal: Drug Deliv Date: 2020-12 Impact factor: 6.419